ENDOCRINE TREATMENT OF HORMONE RECEPTOR POSITIVE BREAST CANCER TYPED AS HAVING A LOW RISK OF RECURRENCE
The invention relates to endocrine therapy for use in a method of treating a hormone-receptor (HR)-positive breast cancer, that is typed as having a low risk of recurrence. The invention further relates to methods of treating an individual with HR-positive breast cancer with endocrine therapy according to the cancer's typed risk of recurrence.
1 . A method of treating a hormone receptor (HR)-positive breast cancer in an individual, comprising administering endocrine therapy to the individual, wherein said cancer is typed as having a low risk of recurrence and wherein said endocrine therapy is administered for more than five years.
2 . The method according to claim 1 , wherein the endocrine therapy comprises an aromatase inhibitor and/or anti-oestrogen therapy.
3 . The method according to claim 1 , wherein the endocrine therapy comprises letrozole and/or tamoxifen.
4 . The method according to claim 1 , wherein the endocrine therapy has a duration of at least six years.
5 . The method according to claim 1 , wherein the cancer is typed using MammaPrint.
6 . The method according to claim 1 , wherein the cancer is considered as having low risk of recurrence if it is typed as MammaPrint low risk (MP-L).
7 . The method according to claim 1 , wherein the individual is a post-menopausal woman.
8 . The method according to claim 1 , wherein the cancer is not typed as MammaPrint ultralow risk (MP-UL).
9 . A method of treating an individual with hormone receptor (HR)-positive breast cancer with endocrine therapy administered for more than five years if said cancer is typed as having low risk of recurrence and treating an individual with HR-positive breast cancer with endocrine therapy administered for five years or less if said cancer is typed as having high risk of recurrence.
10 . The method of treating according to claim 9 , wherein the endocrine therapy administered for more than five years comprises an aromatase inhibitor and/or anti-oestrogen therapy.
11 . The method of treating according to claim 9 , wherein the endocrine therapy administered for more than five years comprises letrozole and/or tamoxifen.
12 . The method of treating according to claim 9 , wherein the endocrine therapy administered for five years or less comprises an aromatase inhibitor and/or anti-oestrogen therapy.
13 . The method of treating according to claim 9 , wherein the endocrine therapy administered for more than five years has a duration of at least six year.
14 . The method of treating according to claim 9 , wherein the cancer is typed using MammaPrint.
15 . The method of treating according to claim 9 , wherein the cancer is considered as having low risk of recurrence if they are typed as MammaPrint low risk (MP-L) and wherein the cancer is considered as having high risk of recurrence if they are typed as MammaPrint high risk (MP-H).
16 . The method of treating according to claim 9 , wherein the individual is a post-menopausal woman
17 . The method of treating according to claim 9 , wherein the individual with HR-positive breast cancer is treated with endocrine therapy administered for five years or less if said cancer is typed as having MammaPrint ultralow risk (MP-UL).